mRNA Therapy to Restore Lymphatic Flow in Secondary Lymphedema

Inclusion Criteria: * Women who developed upper limb lymphedema after surgery for breast cancer hormone receptor positive (HR+) more than 5 years, * Age\> 18 years, * Body mass Index (BMI)\<40, * Stage 2 Lymphedema, moderate (defined by an increase in volume between 20 and 40% compare to the healthy limb), * Lymphedema evolving during at least 6 months, * Patient who adhere to optimized decongestive therapy, including a compression sleeve worn daily, integrated into an educational care pathway for the management of their lymphedema, * Patients information and signed written consent form, * Patients affiliated to a social security system. Exclusion Criteria: * HER2+ breast cancer triple positive, * Other aggressive breast cancers (including triple negative and inflammatory breast cancer), * Active cancer needing chemo- or radio-therapy, * Metastatic breast cancer, * Bilateral breast cancer, * Upper limb peripheral arterial disease ipsilateral to the lymphedema, * History of recent (\< 3 months) upper limb deep venous thrombosis ipsilateral to the lymphedema, * Previous shoulder or orthopedic surgery on lymphedematous arm * Any abnormality of the opposite arm (arm without lymphedema), * Trophic disorders on the lymphedematous arm, * Last episode of cellulitis less than six months, * Recurrent cellulitis, * Patient participating in a clinical trial or having participated in a clinical trial within the previous 3 months or within 5 half-lives of any investigational product Immunosuppressive and anti-inflammatory treatments (topical and anti-inflammatory dermocorticoids and oral corticosteroids) in the 10 days before the injection or within 5 half-lives. * Patient under judicial protection or enable to express consent, * Females who are or plan to be pregnant or breastfeeding during the course of this study, * Women of childbearing potential (WOCBP) who are sexually active and unwilling to use an adequate birth control method (hormonal or physical barrier), * History of cancer other than breast cancer (excepted basalcell carcinoma), * Any acute, chronic, or severe psychiatric condition that may interfere with participation in the study * Unstable, clinically significant neurologic, psychiatric, cardiovascular (eg, pulmonary arterial hypertension, cardiac valvulopathy, orthostatic hypotension/tachycardia), pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or endocrine disease or other abnormality which may impact the ability of the participant to participate or potentially confound the study results. * Known allergy to bovine proteins * Vulnerable patients (persons deprived of their liberty by judicial or administrative decision, persons undergoing psychiatric treatment, persons admitted to a health or social establishment for purposes other than research) according to article L1121-6 of the Public Health Code.